Coherus BioSciences
United States
123 articles with Coherus BioSciences
-
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
7/26/2021
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021.
-
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
7/21/2021
Coherus BioSciences, Inc. today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).
-
Coherus BioSciences Announces New Employment Inducement Grants - July 13, 2021
7/13/2021
Coherus BioSciences, Inc., announced that effective July 6, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of $13.63, the closing trading price on the grant date.
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
Coherus BioSciences to Present at the Bank of America Health Care Conference
5/7/2021
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST.
-
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
5/6/2021
Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session
-
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
4/30/2021
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET,
-
Coherus BioSciences Announces New Employment Inducement Grants - Apr 30, 2021
4/30/2021
Coherus BioSciences, Inc., announced that effective April 28, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $14.76, the closing trading price on the grant date.
-
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting- Toripalimab data will also be featured in ASCO’s official press program -
4/29/2021
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc., announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.
-
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
4/29/2021
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.
-
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
4/23/2021
Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC),
-
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi BiosciencesCoherus received $50 million from sale of 2,491,998 shares at $20.06 per share
4/20/2021
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 stock purchase agreement, Coherus has received $50 million from Junshi Biosciences’ acquisition of 2,491,988 shares at a price per share of $20.06.
-
Coherus Management to Present at Upcoming Investor Conferences
2/25/2021
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March.
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
2/24/2021
Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year
-
Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
2/18/2021
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be followed by an investor conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast.
-
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
2/17/2021
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira® (adalimumab) biosimilar product candidate, and has set a Biosimilar User Fee Act action date for December 2021.
-
Coherus Announces CFO Transition Plans
2/16/2021
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid Stilwell has been appointed to succeed Dr. Viret as CFO. “It has been a sincere pleasure working with Jean over more than six years as we have built Coherus into a growing commercial-stage biotech company. He will alw
-
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a...
-
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
2/2/2021
A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.
-
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
2/1/2021
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada